New Hope for Toddlers with Peanut Allergies: Viaskin Peanut Patch Safety Study Begins

If you’re a parent of a toddler with a peanut allergy, the daily fear of accidental exposure is real. But exciting news is on the horizon!

DBV Technologies has officially launched a promising safety study evaluating the Viaskin® Peanut patch in children aged 1 to 3 years.

What Is the Viaskin Peanut Patch?

This patch, applied to the skin, delivers a tiny, controlled dose of peanut protein with the goal of safely desensitizing the immune system over time. For parents looking for non-invasive peanut allergy treatment options, this could be an option.

The Viaskin Peanut patch is a form of epicutaneous immunotherapy (EPIT). It works by delivering trace amounts of peanut protein through the skin—without requiring ingestion. This unique approach can help train the immune system to tolerate peanuts gradually.

Unlike oral immunotherapy (OIT), which involves eating small amounts of peanut protein, the patch:

• Is worn daily

• Is designed for convenience

• Minimizes the risk of serious allergic reactions

This treatment could be especially helpful for toddlers.

The newly launched study is a Phase 3, placebo-controlled clinical trial that will enroll 480 peanut-allergic toddlers in the U.S. Canada, UK, Europe, and Australia. This study will build on the previous EPITOPE trail that showed 2 out of 3 toddler could tolerate more peanut protein after one year of wearing the patch.

If successful, the patch could be submitted for FDA approval by late 2026.

Going to the allergist? Grab my symptom tracker and testing checklist to help you prepare ahead of time for your appointment.